Analysts project that the global obesity therapeutic market could be worth $100 billion by around 2030, and Barclays estimates the burgeoning weight loss drug industry could reach as high as $200 billion within the next decade. GLP-1 medications support weight loss by sending signals to the brain and body that help regulate metabolism and help patients feel full and satiated longer. In the past year, many telehealth and digital health companies have jumped into the market, offering prescriptions for GLP-1s as part of an existing weight loss or chronic condition management program, or creating a new service line targeting obesity care.
Read the full article: Digital Health Companies Making a Long-Term Play for the $100B Weight Loss Drug Market //
Source: https://www.fiercehealthcare.com/health-tech/telehealth-companies-target-100b-weight-loss-drug-market-patients-grapple-access-costs